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ABSTRACT
Objective: This study was conducted to analyze the impact of universal health coverage in Indonesia, known as Jaminan Kesehatan Nasional (JKN) 
on percentage of patients who did fasting blood glucose (FBG) tests each hospital visit and clinical outcomes (CO) among type 2 diabetes mellitus 
(T2DM) patients.
Methods: We conducted a longitudinal retrospective study to collect the data from 6-month before JKN and 1-year after JKN at three hospitals in 
Jakarta Province. All T2DM outpatient’s services using Asuransi Kesehatan (ASKES) with at least 6 hospital visits were included in the study. The 
subject with double insurances and died before implementation of JKN were excluded from the study. The CO before and after JKN were compared 
with Wilcoxon test.
Results: Total samples that collected were 296 patients divided to predominance female with 166 (56%) and male 125 (44%). From the data, it 
seemed that there were no all patients who did FBG test. We founded 50% of patients had FBG test before JKN. Meanwhile, the percentage at the 
beginning of JKN tended to be lower about 37% than before JKN. Number of patients decreased associate with JKN but number of hospital visit 
increased. Based on FBG level, 17 (9.19%) patients had better CO and this number increased slightly after JKN to 22 (11.89%). In contrast, patients 
with worse FBG level decreased about 9%. More patients had bad stable and less patients had good stable FBG level. Statistical analysis showed that 
CO between before and after JKN had p=0.404 among T2DM outpatients in Type A hospitals and p=0.877 in Type B hospital.
Conclusion: Implementation of JKN had an impact to decrease percentage of patients who did FBG tests and number of patients but raised hospital 
visit. CO was different significantly between before and after JKN among T2DM outpatients in Type A hospitals but was no different in Type B hospital.
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INTRODUCTION
Currently, Indonesian government has implemented universal health 
coverage (UHC), well known as Jaminan Kesehatan Nasional (JKN) since 
1st January 2014. JKN defined as non-profit and comprehensive health 
public insurance for all Indonesian citizen [1,2]. Before implementation 
of JKN, there were a lot of public health insurances. One of them was 
Asuransi Kesehatan (ASKES). ASKES was health public insurance for 
civil servant and pensioner.
There are different payment method between ASKES and JKN. ASKES 
uses “fee for services” method and JKN uses Indonesia Case Base Groups 
(INA-CBGs) method [2]. In INA-CBGs method, cost treatment is limited 
based on diagnose and type of hospital, for example Rp. 362 thousand 
(USD 27.618) and Rp. 165 thousand (USD 12.622) for patients among 
Type A hospitals and Type B hospital, respectively [3]. Consequently, 
hospital will limit services regard to treatment cost from INA-CBGs and 
will impact to patient’s clinical outcomes (CO).
Nowadays, Indonesia was one of the top 10 countries in number of 
people living with diabetes in the world [4]. National health survey 
revealed that the prevalence diabetes in 2013 increased 2 times from 
prevalence in 2007 [5]. As a result, number of type 2 diabetes mellitus 
(T2DM) outpatients will increase in the future and need comprehensive 
services to ensure their CO.
Based on preliminary study in one of Type A hospitals, we founded 
difference of total number of medicine and number of non-generic 
medicine used among T2DM outpatients after implementation of 
JKN [6]. However, we have no data about the influence of these 
differences to CO. Therefore, this study was conducted to understand 
CO among T2DM outpatients between before and after JKN.
METHODS
Study design and data collection
The retrospective longitudinal study was conducted to recruit the 
data from 6 months before JKN and 1 year after JKN (from July 2013 
to December 2014) among T2DM outpatients in 3 Hospital’s Jakarta 
Province, Indonesia. We collected the data, such as socio-demographic, 
profile treatment, hospital visit, and laboratory data, for example fasting 
blood glucose (FBG) in 2 hospitals of Type A and 1 hospital of Type B.
Study subject
This study was approved by ethical committee from three hospitals. 
Subjects in this study were all adult T2DM outpatients who used ASKES, 
public insurance before JKN, and visited hospital routinely at least 
6 times during the period of this study. Subject with double insurances 
and died before implementation of JKN were excluded in this study.
Outcome measurement
Parameter to analyze the CO was FBG. The normal of FBG was 
<126 mg/dL. CO in this study was divided into four categories. The first 
category was better CO that defined as patients showed the improving 
of FBG test to normal. Good stable CO was defined as FBG score always 
normal in every test. Bad stable CO was defined as FBG score always 
higher than normal. Worse CO was defined as FBG score from normal to 
higher score than 126 mg/dL.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i5.17136
Research article
157
Asian J Pharm Clin Res, Vol 10, Issue 5, 2017, 156-160
 Anggriani et al. 
Data analysis
Patients characteristic, number of patients, hospital visit, FBG test, and 
CO were calculated and analyzed using one of statistical software. The 
results were presented as number, mean, and percentage (%). We used 
Wilcoxon test to compare CO before and after JKN.
RESULTS
Sociodemographic characteristic
A total of 291 (100%) patients were enrolled from polyclinic of T2DM 
outpatients who met inclusion criteria at 3 Jakarta’s Hospitals, Indonesia. 
There were 179 patients eligible in type A Hospitals, 43% T2DM 
outpatients were male and 57% were female. We recruited 112 patients in 
Type B hospital. Among of them were 44% male and 56% female. Totally, 
more than female’s T2DM outpatients than male in 3 hospitals. We also 
founded that patients in this study had mean of age 65.91±8.336 (Table 1).
Trend number of patients and hospital visit before and after JKN
According to this study, trend number of patients and hospital visit were 
expressed on Fig. 1. In the first semester of implementation of UHC in 
Indonesia, number of patients dropped in Type A hospitals, but we founded 
number of patients in Type B hospital was similar between before and after 
JKN. However, number of hospital visit among T2DM outpatients increased 
in the first semester of JKN but similar hospital visit with before JKN in the 
second semester. If the whole data were analyzed, number of patients in 3 
Jakarta’s Hospitals showed decreasing after applied JKN and the result also 
performed that number of hospital visit increased in era of JKN.
The impact of JKN on percentage patients who did FBG test in 
hospital visit
As shown in Fig. 2, percentage patients who did FBG test per hospital 
visit per month in three Jakarta’s Hospitals was performed. The 
graph demonstrated not all patients who visited hospital did FBG 
test during the period of study. Only 50% patients had FBG test 
before implementation of JKN in all Hospitals.  In the first semester 
implementation of JKN, this number decreased to 37% patients who did 
FBG test per hospital visit. In contrast, percentage patients who did FBG 
test increased to 64% in September 2014. The decreasing of percentage 
more dramatic in Type B hospital than Type A hospitals.
The impact of UHC in Indonesia on COs among T2DM outpatients
The further results expressed CO associated with FBG. CO is one of 
the essential parameter to measure the impact new insurance, JKN, in 
Indonesia among T2DM outpatients. However, there were no patients did 
FBG test every month, the number patients had met the inclusion criteria 
to analyze the CO were 185 patients from 291 patients. Distribution of 
CO among study population was presented in Fig. 3.
From the data, we founded the percentage of patients with better CO 
increased from 17 (9.19%) patients to 22 (11.89%). In contrast, the 
Table 1: Mean age distribution among gender






Male 76 (43) 49 (44) 125 (43) 67.41±8.373
Female 103 (57) 63 (56) 166 (57) 64.79±8.153
Total 179 (100) 112 (100) 291 (100) 65.91±8.336
Data are expressed as number (percentage); mean±SD. SD: Standard deviation
Fig. 1: Number of patients and hospital visit between before and after Jaminan Kesehatan Nasional from July 2013 to December 2014
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percentage of patients with better worse CO decreased from 13.51% 
to 9% after implementation of JKN. This result clearly clarified that 
CO improved after JKN. In the other hand, the result was reported that 
patients with good stable CO in era of JKN lower than before JKN and 
number of patients with bad stable tended to increase after JKN. We 
assumed that CO was not improved associated with these categories. 
To compare CO between before and after JKN, We also analyzed the CO 
using Wilcoxon test because the data distributed non-normal. Statistical 
analysis among T2DM outpatients in Type A hospitals demonstrated 
p=0.404. In the other hand, p value was 0.877 for T2DM outpatients 
in Type B hospital. Meanwhile, p value for differences of CO before and 
after JKN at three hospitals was 0.524.
Fig. 3: Distribution of clinical outcomes among type 2 diabetes mellitus outpatients before and after Jaminan Kesehatan Nasional. Data 
expressed as percentage from total of patients
Fig. 2: Percentage of fasting blood glucose per hospital visite from July 2013 to December 2014. Data expressed as percentage from total 
of hospital visit per month
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DISCUSSION
In this study, there was predominance of female then followed by 
male. A study by Wilson et al. in Ontario also had similar report [7]. 
This result was linier with RISKESDAS by Ministry of Health (MoH) [8] 
and result study in Mexico [9]. Most of the T2DM patients in this study 
were geriatric because one risk factor to get T2DM was age more than 
45 years old [10].
In era of JKN, health services and facilities were divided to primary 
health-care facility and higher level facility. The primary health-care 
facility was community health center, known as Puskesmas, a private 
clinic, or a TNI-Polri clinic which has collaboration with the Social 
Security Administration Agency, known as BPJS. BPJS is agency that 
responsibility of JKN program. The next health service is higher level 
facility such as hospital. Patients can be accessed this facility only based 
on referral from the primary health-care facility, except for emergency. 
If this procedure is not followed, JKN will not cover the treatment 
cost [11].
This study founded number of patient decreased after implementation 
of JKN as shown in Fig. 1. It was caused by refer back program. Based 
on Minister Decree no 28 years 2014, diabetes mellitus is one of the 
chronic disease [12]. T2DM outpatients who have not complication and 
blood glucose were stable should go to primary health care, known as 
refer back program. T2DM patients will get recommendation letter from 
doctor in higher level health service and facilities to register refer back 
program in BPJS. Patients with refer back program will visit the doctor 
and get medicine in primary health care. Every 3 month, patients will be 
allowed to higher level facilities and see a doctor. If the diagnose is good, 
the patients will transfer to primary health care as member of refer back 
program [11]. The implementation of refer back program is still need 
socialization. A study in Ternate reported that official understanding 
of the policy reference was still relative poorly [13]. Another problem 
in this program was inappropriate refer back program because limited 
facilities, drug availability, and human resources [14].
Furthermore, we analyzed the impact of JKN to number of hospital 
visit. However, number of patients dropped after launched JKN, number 
of hospital visit raised in the first semester of JKN (Fig.1). One of the 
reasons related to this condition was the different payment method in 
era of JKN. JKN used INA-CBGs method that only cover cost of medicine 
for 7 days. T2DM patients need medicine for 30 days a month to maintain 
blood glucose concentration. In contrast, T2DM patients get medicine 
for 30 days that was covered by ASKES. Consequently, many T2DM 
patients disappointed for this program and patients have to visit more 
frequent. Other study revealed that patient’s satisfaction was lower in 
era of JKN than ASKES [15]. Nugraheni et al. (2015) also reported that 
JKN’s patient was unsatisfied through services [16]. Government tried 
to solve this problem that chronic disease, mainly diabetes mellitus will 
get the medicines for 30 days [11]. Medicines of 7 days will be covered 
by INA-CBGs method, and medicine of 23 days will be covered by fee for 
service method. As a result, patients had to visit hospital more than one 
time to get the medicine.
On the other hand, in the beginning of this announcement, not all 
patients understood with this issue. As a result, BPJS also have declared 
the decree no 38 year 2014 to support the previous decree from MoH 
[17]. This decree had positive impact to increase hospital visit and 
became similar with hospital visit before JKN.
The next our result demonstrated FBG test per hospital visit decreased 
in the first semester and start to increase in the second semester of JKN 
(Fig. 2). There were many problems in the beginning of implementation 
of JKN especially in the first semester of JKN. The limitation of cost 
treatment based on diagnoses (INA-CBGs method) also contributed 
this problem. This decreasing was more significant in Type B hospital 
than Type A hospitals. It was caused cost treatment that was covered 
based on INA-CBGS method in Type A hospitals was bigger than 
Type B hospital, Rp. 362 thousand (USD 27.618) and Rp. 165 thousand 
(USD 12.622), respectively [4]. Another study reported real treatment 
cost T2DM outpatients higher the INA-CBG’s standard [18]. It will 
associate with the limitation services to patients.
CO is one of the essential parameter to audit the new insurance, JKN. 
Hemoglobin A1C (HbA1C) and FBG test are parameters to measure CO 
among T2DM patients [19-21]. We collected HbA1C and FBG test in 
this study. The data of HbA1C were very limited. Haghighatpanah et al. 
(2016) founded moderate correlation and the sensitivity, specificity 
among FBG and HbA1C [22]. Because of that, we considered to use 
FBG test to analyze the CO among T2DM outpatients. Other studies 
were reported using FBG test to analyze improved outcome with T2DM 
outpatients [23-26]. This study was linier with Jones et al. (2004) 
used FBG to observe the effect of insulin among diabetes mellitus 
patients [27].
We divided COs into four categories that were better, good stable, bad 
stable, and worse CO. The data were non-normal distributed. As a result, 
we used Wilcoxon test related to find the differences CO between before 
and after JKN. There was no significant different (p>0.05) CO among 
T2DM outpatients after implementation of JKN in Type B hospital. 
Nevertheless, statistical analysis expressed that p<0.05 among T2DM 
outpatients in Type A hospitals. It defined as CO was not similar before 
and after JKN. T2DM outpatients in Type A hospital performed improved 
CO. On the other hand, the result of Wilcoxon test from combination 
of CO from all hospitals showed p>0.05. Improved CO among T2DM 
outpatient in Type A hospitals related to higher cost treatment that was 
covered by JKN. Consequently, T2DM outpatients will get more services 
than patients in Type B hospitals and also impact to CO. Another study 
at one hospital in Bali, Indonesia founded that patients with JKN showed 
a greater reduction of blood glucose concentration and lower side effect 
than non-JKN’s patients [28].
CONCLUSION
JKN as a new public health insurance in Indonesia had impact to increase 
hospital visit and decreased number of patients. The percentage of FBG 
test per hospital visit dropped in the first semester implementation of 
JKN and this percentage raised in the second semester of JKN. CO was 
different significantly among T2DM outpatients in Type A hospital but 
was no different in Type B hospital.
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